Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial-Reference-Cited by-同舟云学术

Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial

Published:2022-08 Issue:8 Volume:28 Page:1151.e9-1151.e16
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Trujillo-Rodríguez María,Muñoz-Muela Esperanza,Serna-Gallego Ana,Milanés-Guisado Yusnelkis,Praena-Fernández Juan Manuel,Álvarez-Ríos Ana Isabel,Herrera-Hidalgo Laura,Domínguez Montserrat,Lozano Carmen,Romero-Vazquez Gloria,Roca Cristina,Espinosa Nuria,Gutiérrez-Valencia Alicia,López-Cortés Luis F.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference25 articles.

1. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy;Havlir;N Engl J Med,1998

2. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials;Arribas;HIV Med,2016

3. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients;Gutierrez-Valencia;PLoS One,2018

4. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens;López-Cortés;PLoS One,2016

5. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA);The Journal of Infectious Diseases;2024-09-03

2. Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors;Frontiers in Immunology;2024-07-11

3. HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch;Viruses;2024-02-23

4. The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers;Journal of Clinical Investigation;2024-02-20

5. HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors;Biomedicine & Pharmacotherapy;2023-12